文献速递间质性肺疾病

转录组分析揭示吡非尼酮治疗特发性肺纤维化的多通路效应

Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis.
PubMed 文献 · Eur Respir J · 2018-11-22

本研究采用比较转录组学方法,分析接受或不接受吡非尼酮治疗的IPF患者的肺匀浆和肺成纤维细胞。结果显示吡非尼酮在成纤维细胞中主要影响生长和细胞分裂通路,在肺匀浆中主要与炎症相关过程有关,并发现CEMIP表达下调。

要点

  • 吡非尼酮在IPF成纤维细胞中主要调控生长与细胞分裂通路。
  • 肺匀浆中吡非尼酮治疗主要关联炎症相关过程。
  • CEMIP在治疗患者肺匀浆和成纤维细胞中表达降低,血浆CEMIP治疗后下降。

核心结论

  • 吡非尼酮通过作用于成纤维细胞和其他肺细胞的多条通路,控制细胞外基质结构和炎症反应发挥有益效应。

研究设计与样本

  • 采用比较转录组学方法,分析接受或不接受吡非尼酮治疗的IPF患者的肺匀浆和肺成纤维细胞。

主要发现

  • 在成纤维细胞中,吡非尼酮主要影响生长和细胞分裂通路,提示细胞代谢转变。
  • 在肺匀浆中,吡非尼酮主要与炎症相关过程有关。
  • 在成纤维细胞和肺匀浆中,调控基因在基因本体节点「细胞外基质」中过表达。
  • 接受吡非尼酮治疗的IPF患者肺匀浆和成纤维细胞中CEMIP表达较低。
  • IPF患者血浆CEMIP水平高于健康对照,吡非尼酮治疗7个月后下降。

关键数值与推荐

  • IPF患者血浆CEMIP水平高于健康对照,吡非尼酮治疗7个月后下降。
  • CEMIP沉默减少IPF成纤维细胞胶原产生并减弱增殖和迁移。

临床怎么用

  • 吡非尼酮的治疗效应涉及成纤维细胞和炎症等多通路,提示其作用不限于单一细胞靶点。
  • 血浆CEMIP可能作为吡非尼酮治疗反应的潜在标志物,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the beneficial effects of pirfenidone in treating idiopathic pulmonary fibrosis (IPF), it remains unclear if lung fibroblasts (FB) are the main therapeutic target.To resolve this question, we employed a comparative transcriptomic approach and analysed lung homogenates (LH) and FB derived from IPF patients treated with or without pirfenidone.In FB, pirfenidone therapy predominantly affected growth and cell division pathways, indicating a major cellular metabolic shift. In LH samples, pirfenidone treatment was mostly associated with inflammation-related processes. In FB and LH, regulated genes were over-represented in the Gene Ontology node "extracellular matrix". We identified lower expression of cell migration-inducing and hyaluronan-binding protein (CEMIP) in both LH and FB from pirfenidone-treated IPF patients. Plasma levels of CEMIP were elevated in IPF patients compared to healthy controls and decreased after 7 months of pirfenidone treatment. CEMIP expression in FB was downregulated in a glioma-associated oncogene homologue-dependent manner and CEMIP silencing in IPF FB reduced collagen production and attenuated cell proliferation and migration.Cumulatively, our approach indicates that pirfenidone exerts beneficial effects via its action on multiple pathways in both FB and other pulmonary cells, through its ability to control extracellular matrix architecture and inflammatory reactions.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Kwapiszewska G, Gungl A, Wilhelm J, et al. Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis. Eur Respir J. 2018. PMID: 30166321. doi:10.1183/13993003.00564-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。